Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Cencora Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zoetis (ZTS), Cencora (COR) and Corbus Pharmaceuticals (CRBP). Zo...

Analysts Conflicted on These Healthcare Names: Zoetis (ZTS), Cencora (COR) and Corbus Pharmaceuticals (CRBP)

Electrocore (($ECOR)) has held its Q1 earnings call. Read on for the main highlights of the call. ElectroCore’s latest earnings call painted a larg...

ElectroCore Earnings Call Highlights Growth And Risks

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Dynatrace (DT) and Core Scientific Inc (CORZ) with b...

Analysts Offer Insights on Technology Companies: Dynatrace (DT) and Core Scientific Inc (CORZ)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cencora (COR), LeonaBio (LONA) and Assertio Therapeutics (ASRT). ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cencora (COR), LeonaBio (LONA) and Assertio Therapeutics (ASRT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cencora (COR) and Enovis (ENOV) with bullish sentime...

Analysts Are Bullish on These Healthcare Stocks: Cencora (COR), Enovis (ENOV)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Electrocore (ECOR) and Warby Parker (WRBY) with bull...

Analysts Are Bullish on These Healthcare Stocks: Electrocore (ECOR), Warby Parker (WRBY)

In a report released today, Allen Lutz from Bank of America Securities maintained a Hold rating on Cencora, with a price target of $280.00. Lutz co...

Cencora (COR) Gets a Hold from Bank of America Securities

Needham analyst John Todaro reiterated a Buy rating on Core Scientific Inc today and set a price target of $29.00. Todaro covers the Financial sect...

Needham Keeps Their Buy Rating on Core Scientific Inc (CORZ)

In a report released today, Glen Santangelo from Barclays maintained a Buy rating on Cencora, with a price target of $425.00. According to TipRanks...

Barclays Reaffirms Their Buy Rating on Cencora (COR)

Analysts have been eager to weigh in on the Technology sector with new ratings on Procore Technologies (PCOR), Alight (ALIT) and Advanced Micro Dev...

Analysts Offer Insights on Technology Companies: Procore Technologies (PCOR), Alight (ALIT) and Advanced Micro Devices (AMD)

Core Scientific Inc ( ($CORZ) ) has shared an update. On May 6, 2026, Core Scientific’s subsidiary Core Scientific Finance I LLC completed a $3.3 b...

Core Scientific Raises $3.3 Billion in Secured Notes

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cencora (COR), Orthofix Medical (OFIX) and Pfizer ...

Analysts Offer Insights on Healthcare Companies: Cencora (COR), Orthofix Medical (OFIX) and Pfizer (PFE)

There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on WISeKey International Holding (WKEY), FTC Solar (FTC...

Analysts Are Bullish on Top Technology Stocks: WISeKey International Holding (WKEY), FTC Solar (FTCI)

Core Scientific’s ($CORZ) shares climbed roughly 10% on Wednesday afternoon after the data center operator said it has agreed to acquire Polaris DS...

Core Scientific Stock (CORZ) Jumps 10% on Polaris Buyout after Failed CoreWeave Merger

There’s a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on GlobalFoundries Inc (GFS) and Procore Technologies (...

Analysts Offer Insights on Technology Companies: GlobalFoundries Inc (GFS) and Procore Technologies (PCOR)

Canaccord Genuity analyst Edward Nash reiterated a Buy rating on Corcept Therapeutics today and set a price target of $110.00. According to TipRank...

Canaccord Genuity Remains a Buy on Corcept Therapeutics (CORT)

Barclays analyst Saket Kalia maintained a Buy rating on Procore Technologies today and set a price target of $65.00. According to TipRanks, Kalia i...

Procore Technologies (PCOR) Gets a Buy from Barclays

The latest update is out from Corcept Therapeutics ( ($CORT) ). On April 30, 2026, Corcept Therapeutics reported first quarter 2026 revenue of $164...

Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth

Canaccord Genuity analyst Tim Huff reiterated a Buy rating on Ecora Royalties PLC today and set a price target of p185.00. According to TipRanks, H...

Canaccord Genuity Sticks to Their Buy Rating for Ecora Royalties PLC (ECOR)

Berenberg Bank analyst reiterated a Buy rating on Ecora Royalties PLC today and set a price target of p180.00. Currently, the analyst consensus on ...

Market Cap	$64.51B	P/E Ratio	15.35
52W High	$377.54	52W Low	$244.82
Div Yield	240.0%	Payout Ratio	18.0%
EPS Growth 3Y	-0.5%	52W Position	21.3%
Overall Score	48	Value Score	50
Quality Score	68	Technical Score	27

EPS Current Est	$17.79	EPS Next Est	$19.69
EPS Growth Est	+10.7%	DPS Growth 3Y	6.1%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	COR	$273.03	-0.68%	642.56K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	COR	$273.03	-0.7%	642.56K
3
4
5
6

COR

COR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Cencora Inc. Data in Excel

Get Cencora Inc. Data in Excel